Evaluation Efficacy and Safety of Vortioxetine 20 mg/d versus Placebo for Treatment Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Masoud Behzadifar^1,2, Hamidreza Dehghan¹, Korush Saki³, Meysam Behzadifar⁴, Abouzar Keshavarzi¹, Maryam Saran⁵, Ali Akbari Sari^6*

¹Department of Health, Yazd University of Medical Sciences, Yazd, Iran.
²Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
³Department of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
⁴Department of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
⁵Department of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
⁶Department of Health Management and Economics, Tehran University of Medical Sciences, Tehran, Iran.

DOI: 10.4236/pp.2015.64024                

Abstract

Major depressive disorder, a common debilitating illness, is one of the leading causes of disability and disease worldwide. Different drugs for the treatment of patients with major depression can be used. Vortioxetine for the treatment of major depressive disorder was approved by the Food and Drug Administration (FDA) in 2013. This study aimed to evaluation efficacy and safety Vortioxetine 20 mg/d compared placebo in major depressive disorder. To conduct this study, we searched Pub Med, Cochrane library, Scopus, and Central Register of Controlled Trials. This study by including randomized controlled trials (RCTs) that evaluated this study by including randomized controlled trials (RCTs) that evaluated Vortioxetine 20 mg/d in patients with major depressive disorder. Data analysis was conducted by standard mean different ratios (SMD) with 95% confidence intervals (CIs), P values and odds ratios (ORs) for adverse events with 95% confidence intervals (CIs) and P values; heterogeneity testing and sensitivity analysis was also performed in this study. We found that 4 articles met the inclusion criteria and were finally used for this meta-analysis. Results showed statistical significance in the MADRS (Montgomery-Åsberg Depression Rating Scale), SMD = -4.75 with 95% CI [-6.84, -2.65] and P value < 0.00001), for Clinical Global Impression Scale-Improvement (CGI-I) SMD was -4.34 with 95% CI [-6.41, -2.27] and P value < 0.00001, and for Sheehan Disability Scale (SDS) SMD was -2.62 with 95% CI [-3.99, -1.25] and P value < 0.00001. The pooled analysis for safety demonstrated for diarrhea OR = 0.92 with 95% CI [0.46, 1.83] , P value = 0.09, for dry mouth OR = 1.74 with 95% CI [1.07, 2.83] , P value = 0.80, for dizziness OR = 1.62 with 95% CI [0.72, 3.66] , P value = 0.05, for fatigue OR = 1.17 with 95% CI [0.34, 4.08], P value = 0.07, for headache OR = 1.28 with 95% CI [0.91, 1.79], P value = 0.60 and for nausea OR = 4.78 with 95% CI [3.43, 6.67], P value = 0.61. Vortioxetine 20 mg/d versus placebo showed a significant difference for nausea and dry mouth, but no significant differences were observed for the four adverse effects. In several studies of the drug Vortioxetine 20 mg/d, the treatment of major depressive illness has been more effective for evaluating the effectiveness of this drug, which must be more clinical studies of sound.

Keywords

Major Depressive Disorder, Vortioxetine 20 mg, Systematic Review, Meta-Analysis

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Ferrari, A.J., Charlson, F.J., Norman, R.E., et al. (2013) Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. PLoS Medicine, 10, e1001547.
[2]	World Health Organization Mental Health Depression. http://www.who.int/mediacentre/factsheets/fs369/en/
[3]	Murray, C.J. and Lopez, A.D. (1997) Alternative Projections of Mortality and Disability by Cause 1990-2020: Global Burden of Disease Study. The Lancet, 349, 1498-1504. http://dx.doi.org/10.1016/S0140-6736(96)07492-2
[4]	Souery, D., Papakostas, G.I. and Trivedi, M.H. (2006) Treatment Resistant Depression. Journal of Clinical Psychiatry, 67, 16-22.
[5]	Liu, M.T., Maroney, M.E. and Hermes-DeSantis, E.R. (2015) Levomilnacipran and Vortioxetine: Review of New Pharmacotherapies for Major Depressive Disorder. World Journal of Pharmacology, 4, 17-30. http://dx.doi.org/10.5497/wjp.v4.i1.17
[6]	Halperin, D. and Reber, G. (2007) Influence of Antidepressants on Hemostasis. Dialogues in Clinical NeuroSciences, 9, 47-59.
[7]	National Institute of Mental Health What Is Depression? http://www.nimh.nih.gov/health/topics/depression/index.shtml
[8]	Centers for Disease Control and Prevention Depression. http://www.cdc.gov/mentalhealth/basics/mental-illness/depression.htm
[9]	American Psychiatric Association (2013) DSM-5 Task Force. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition, American Psychiatric Association, Washington DC.
[10]	Wesolowska, A., Tatarczynska, E., Nikiforuk, A. and Chojnacka-Wojcik, E. (2007) Enhancement of the Anti Immobility Action of Anti-Depressants by a Selective 5-HT7 Receptor Antagonist in the Forced Swimming Test in Mice. European Journal of Pharmacology, 555, 43-47. http://dx.doi.org/10.1016/j.ejphar.2006.10.001
[11]	Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gøtzsche, P.C., Ioannidis, J.P.A., et al. (2009) The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Medicine, 6, e1000100. http://dx.doi.org/10.1371/journal.pmed.1000100
[12]	Montgomery, S.A. and Asberg, M. (1979) A New Depression Scale Designed to Be Sensitive to Change. The British Journal of Psychiatry, 134, 382-389. http://dx.doi.org/10.1192/bjp.134.4.382
[13]	Forkmann, T., Scherer, A., Boecker, M., Pawelzik, M., Jostes, R. and Gauggel, S. (2011) The Clinical Global Impression Scale and the Influence of Patient or Staff Perspective on Outcome. BMC Psychiatry, 11, 83. http://dx.doi.org/10.1186/1471-244X-11-83
[14]	Leon, A.C., Olfson, M., Portera, L., Farber, L. and Sheehan, D.V. (1997) Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale. The International Journal of Psychiatry in Medicine, 27, 93-105. http://dx.doi.org/10.2190/T8EM-C8YH-373N-1UWD
[15]	Higgins, J.P., Altman, D.G., Gøtzsche, P.C., Jüni, P., Moher, D., Oxman, A.D., Savovic, J., Schulz, K.F., Weeks, L. and Sterne, J.A. (2011) The Cochrane Collaboration’s Tool for Assessing Risk of Bias in Randomized Trials. BMJ, 343, Article ID: d5928.
[16]	Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J. and Mc Quay, H.J. (1996) Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary? Controlled Clinical Trials, 17, 1-12. http://dx.doi.org/10.1016/0197-2456(95)00134-4
[17]	Egger, M., Davey Smith, G., Schneider, M. and Minder, C. (1997) Bias in Meta-Analysis Detected by a Simple, Graphical Test. BMJ, 315, 629-634. http://dx.doi.org/10.1136/bmj.315.7109.629
[18]	Begg, C.B. and Mazumdar, M. (1994) Operating Characteristics of a Rank Correlation Test for Publication Bias. Biometrics, 50, 1088-1101. http://dx.doi.org/10.2307/2533446
[19]	Boulanger, J.P., Loft, H. and Olsen, C.K. (2014) Efficacy and Safety of Vortioxetine (Lu AA21004), 15 and 20 mg/day: A Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced Study in the Acute Treatment of Adult Patients with Major Depressive Disorder. International Clinical Psychopharmacology, 29, 138-149. http://dx.doi.org/10.1097/YIC.0000000000000018
[20]	Mahableshwarkar, A.R., Jacobsen, P.L., Serenko, M., et al. (2013) A Duloxetine-Referenced, Fixed-Dose Study Comparing Efficacy and Safety of 2 Vortioxetine Doses in the Acute Treatment of Adult MDD Patients (NCT01153009) (Poster). American Psychiatric Association 166th Annual Meeting, San Francisco, 18-22 May 2013.
[21]	Jacobsen, P.L., Mahableshwarkar, A.R., Serenko, M., et al. (2013) A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Vortioxetine 10 mg and 20 mg in Adults with Major Depressive Disorder (NCT01163266) (Poster). American Psychiatric Association 166th Annual Meeting, San Francisco, 18-22 May 2013.
[22]	Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder. NCT01255787. http://clinicaltrials.gov/show/NCT01255787
[23]	Alvarez, E., Perez, V., Dragheim, M., Loft, H. and Artigas, F. (2012) A Double-Blind, Randomized, Placebo-Controlled, Active Reference Study of Lu AA21004 in Patients with Major Depressive Disorder. International Journal of Neuropsychopharmacology, 15, 589-600. http://dx.doi.org/10.1017/S1461145711001027
[24]	Mahableshwarkar, A.R., Jacobsen, P.L. and Chen, Y. (2013) A Randomized, Double-Blind Trial of 2.5 mg and 5 mg Vortioxetine (Lu AA21004) versus Placebo for 8 Weeks in Adults with Major Depressive Disorder. Current Medical Research & Opinion, 29, 217-226. http://dx.doi.org/10.1185/03007995.2012.761600
[25]	Jain, R., Mahableshwarkar, A.R., Jacobsen, P.L., Chen, Y. and Thase, M.E. (2013) A Randomized, Double-Blind, Placebo-Controlled 6-wk Trial of the Efficacy and Tolerability of 5 mg Vortioxetine in Adults with Major Depressive Disorder. International Journal of Neuropsychopharmacology, 16, 313-321. http://dx.doi.org/10.1017/S1461145712000727
[26]	Katona, C., Hansen, T. and Olsen, C.K. (2012) A Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of Lu AA21004 in Elderly Patients with Major Depressive Disorder. International Clinical Psychopharmacology, 27, 215-223. http://dx.doi.org/10.1097/YIC.0b013e3283542457
[27]	Henigsberg, N., Mahableshwarkar, A.R., Jacobsen, P., Chen, Y. and Thase, M.E. (2012) A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults with Major Depressive Disorder. The Journal of Clinical Psychiatry, 73, 953-959. http://dx.doi.org/10.4088/JCP.11m07470
[28]	Penninx, B.W., Beekman, A.T., Honig, A., Deeg, D.J., Schoevers, R.A., van Eijk, J.T. and van Tilburg, W. (2001) Depression and Cardiac Mortality: Results from a Community-Based Longitudinal Study. Archives of General Psychiatry, 58, 221-227. http://dx.doi.org/10.1001/archpsyc.58.3.221
[29]	Schlienger, J.L. (2013) Type 2 Diabetes Complications. La Presse Médicale, 42, 839-848. http://dx.doi.org/10.1016/j.lpm.2013.02.313
[30]	Robinson, R.G. and Spalletta, G. (2010) Post Stroke Depression: A Review. Canadian Journal of Psychiatry, 55, 341-349.
[31]	Di Florio, A., Forty, L., Gordon-Smith, K., Heron, J., Jones, L., Craddock, N. and Jones, I. (2013) Perinatal Episodes across the Mood Disorder Spectrum. JAMA Psychiatry, 70, 168-175. http://dx.doi.org/10.1001/jamapsychiatry.2013.279
[32]	Fu, J. and Chen, Y. (2015) The Efficacy and Safety of 5 mg/d Vortioxetine Compared to Placebo for Major Depressive Disorder: A Meta-Analysis. Psychopharmacology, 232, 7-16. http://dx.doi.org/10.1007/s00213-014-3633-z